Skip to main content
Erschienen in:

26.03.2020 | Original Paper

Expression of HIF-2a in clear-cell renal cell carcinoma independently predicts overall survival

verfasst von: Konstantinos Gkagkalidis, Spyridon Kampantais, Georgios Dimitriadis, Victoras Gourvas, Dorothea Kapoukranidou, Maria Mironidou-Tzouveleki

Erschienen in: Medical Molecular Morphology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study is to evaluate the expression and the prognostic role of main factors, involved in the hypoxia pathway, in patients with clear-cell renal cell carcinoma (ccRCC). Immunohistochemical expression of Hypoxia inducible factors (HIF) HIF-1a, HIF-2a, prolyl hydroxylases PHD1, PHD2, PHD3, and factor inhibiting HIF (FIH) was assessed on a tissue microarray, containing tumour and corresponding normal kidney tissue from 66 patients underwent surgery for ccRCC. Expression levels were evaluated in relation to T stage, Fuhrman grade, cancer-specific, and overall survival (OS). Cytoplasmatic expression of HIF-2a was positively correlated with expression of HIF-1a (p = 0.011). HIF-1a expression was also positively correlated with PHD3 and FIH (p = 0.020 and p = 0.039). Expression of HIF-1a was associated with lower Fuhrman grade (p = 0.008), while HIF-2a overexpression with unfavourable grade (p = 0.026). PHD3 was significant downregulated (84.8%). Age, LDH, presence of necrosis, Fuhrman grade, T stage, and HIF-2a cytoplasmatic expression were significant associated with OS of patients in univariable analysis. In multivariable analysis, HIF-2a expression (p = 0.006) and T stage (p = 0.001) remained as the only independent predictors for overall survival. These results indicate that HIF-2a overexpression not only is inversely correlated with Fuhrman grade in ccRCC, but also represents a strong independent prognostic factor for a poor overall survival.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
4.
Zurück zum Zitat Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92(12):5510–5514CrossRefPubMedPubMedCentral Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92(12):5510–5514CrossRefPubMedPubMedCentral
11.
13.
Zurück zum Zitat Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B (2005) The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11(3):1129–1135PubMed Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B (2005) The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11(3):1129–1135PubMed
14.
Zurück zum Zitat Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1(3):237–246CrossRefPubMed Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1(3):237–246CrossRefPubMed
15.
Zurück zum Zitat Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD (2002) The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1(3):247–255CrossRefPubMed Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD (2002) The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1(3):247–255CrossRefPubMed
16.
20.
22.
Zurück zum Zitat Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J (2016) Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539(7627):112–117. https://doi.org/10.1038/nature19796CrossRefPubMedPubMedCentral Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J (2016) Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539(7627):112–117. https://​doi.​org/​10.​1038/​nature19796CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, Cheng T, Czerwinski RM, Dixon DD, Goggin BS, Grina JA, Halfmann MM, Maddie MA, Olive SR, Schlachter ST, Tan H, Wang B, Wang K, Xie S, Xu R, Yang H, Josey JA (2016) A small-molecule antagonist of HIF2α is efficacious in preclinical models of renal cell carcinoma. Cancer Res 76(18):5491–5500. https://doi.org/10.1158/0008-5472.CAN-16-0473CrossRefPubMed Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, Cheng T, Czerwinski RM, Dixon DD, Goggin BS, Grina JA, Halfmann MM, Maddie MA, Olive SR, Schlachter ST, Tan H, Wang B, Wang K, Xie S, Xu R, Yang H, Josey JA (2016) A small-molecule antagonist of HIF2α is efficacious in preclinical models of renal cell carcinoma. Cancer Res 76(18):5491–5500. https://​doi.​org/​10.​1158/​0008-5472.​CAN-16-0473CrossRefPubMed
Metadaten
Titel
Expression of HIF-2a in clear-cell renal cell carcinoma independently predicts overall survival
verfasst von
Konstantinos Gkagkalidis
Spyridon Kampantais
Georgios Dimitriadis
Victoras Gourvas
Dorothea Kapoukranidou
Maria Mironidou-Tzouveleki
Publikationsdatum
26.03.2020
Verlag
Springer Singapore
Erschienen in
Medical Molecular Morphology / Ausgabe 4/2020
Print ISSN: 1860-1480
Elektronische ISSN: 1860-1499
DOI
https://doi.org/10.1007/s00795-020-00249-3

Neu im Fachgebiet Pathologie

Overview of a comparative analysis of microsatellite instability and standard mismatch repair protein-deficiency tests in a large cancer cohort

  • Hauptreferate: Hauptprogramm der DGP

A retrospective analysis was carried out based on a large cancer patient cohort of our institute ( n  = 1306; collected from 2018 to 2023). dMMR was tested by four IHC reactions (MLH1 and PMS2 or MSH2 and MSH 6). Further, parallel pentaplex …

Molekulare Testung bei mesenchymalen Neoplasien: Was, wann und wie testen?

Mit dem weit verbreiteten Einsatz diverser molekularer Methoden in der histopathologischen Routinediagnostik hat die Tumorklassifikation in den letzten beiden Jahrzehnten signifikante Fortschritte gemacht. Dabei wurden zum einen zahlreiche …

Reconstructing 3D histological structures using machine learning (artificial intelligence) algorithms

  • Hauptreferate: Hauptprogramm der DGP

Artificial intelligence (AI) has recently been applied to pathological and medical image analysis with high sensitivity and specificity [ 1 , 2 ], aiding in various dental diagnostic techniques. The use of AI in image annotation has enhanced the …

Key considerations when implementing new diagnostic technologies in routine practice

  • Hauptreferate: Arbeitsgemeinschaften der DGP

This review explores several key considerations that are critical for implementing new diagnostic technologies into routine practice. These elements will provide a comprehensive guide for navigating the complexities of integrating cutting-edge …